actin binding raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2025-10-23 and is reviewed periodically as new material appears.
The seven-residue chain carries several polar and charged side chains, so it dissolves readily in water and in aqueous buffers near neutral pH. No cysteine is present, so disulphide formation is not a concern and reducing agents are unnecessary. Dilute ammonium hydroxide or acetonitrile-water mixtures are sometimes used for stock solutions when initial dissolution is slow. Strongly alkaline conditions and prolonged contact with oxidising agents are avoided because they can modify lysine-containing stretches, and haze in solution usually signals incomplete dissolution or aggregated material.
Identity and purity are checked with reversed-phase high-performance liquid chromatography, which separates the target sequence from truncated or deletion analogues, and with mass spectrometry, which confirms the expected molecular mass. Amino acid analysis and peptide mapping give orthogonal confirmation but are used less often outside specialist laboratories. Counter-ion content varies: material purified on trifluoroacetic acid gradients retains trifluoroacetate, and ion exchange can convert the salt form. Residual water and solvent are measured by Karl Fischer titration or thermogravimetric analysis, and any purity figure should be read together with the method used to obtain it.
Lyophilised peptide powders are hygroscopic, and the fragment absorbs atmospheric moisture when a vial is opened at room temperature. Weighing and aliquoting are normally done quickly in a dry environment, and stock solutions are divided into single-use portions before freezing. Repeated freeze-thaw cycles are avoided because they promote aggregation and can shift the measured content of a vial. These practices are general to synthetic peptides rather than unique to this sequence, but they matter more for short chains kept for long periods.
No major regulatory agency has approved TB-500 for therapeutic use, and it holds no pharmacopoeial monograph. The name appears on the World Anti-Doping Agency prohibited list within the class covering peptide hormones, growth factors, and related substances. Detection in doping control relies on mass spectrometric methods applied to urine, often after preparation steps that concentrate the analyte. Discussion of TB-500 therefore clusters in biochemistry, sports medicine, and anti-doping literature rather than in registered clinical trials.
TB-500 is a synthetic peptide preparation marketed under a name derived from thymosin beta-4, a 43-residue actin-binding protein first isolated from thymus tissue. The full-length protein has a reported molecular mass near 4963 Da, while material sold as TB-500 is often described as a fragment containing the actin-binding motif LKKTETQ. Because suppliers use the name inconsistently, published sources sometimes refer to the same label as a fragment, a synthetic copy, or a related analog. This naming ambiguity complicates direct comparison of reports across studies.
| Property | Value | Notes |
|---|---|---|
| Water content | Low in freshly lyophilised material | Rises after repeated opening of the same vial |
| Solution stability | Lower than powder stability | Frozen aliquots are preferred over repeated thawing |
| Purity assessment | Reversed-phase HPLC with UV detection | Peak-area percentage excludes salts and water |
| Salt form | Often the trifluoroacetate salt | Retained from acidic purification gradients |
| Light sensitivity | Not strongly photoreactive | Dark storage still advised for long-term keeping |
The most frequently cited identity is a seven-residue fragment with the sequence LKKTETQ, taken from the actin-binding domain of the parent protein. A separate molecule, N-acetyl-seryl-aspartyl-lysyl-proline, often shortened to Ac-SDKP, derives from the same protein's N-terminal region and appears in overlapping literature. Reported molecular masses therefore differ between sources, and a mass value on its own does not establish which fragment is present. Confirmation requires a defined sequence rather than a single number.
Research interest in thymosin beta-4 fragments centres on actin sequestration, cell migration and tissue repair models. Most published work uses cultured cells or animal wound and cardiac preparations, and findings are generally described as preliminary. No fragment of this protein has been approved as a therapeutic product by major regulators. Reviews of the field note inconsistent dosing, delivery routes and outcome measures across studies, which complicates direct comparison. The material is best understood as a laboratory reagent with an active but unresolved research literature.
Interest in the fragment grew during the 1990s and 2000s, when it moved from laboratory work into sports and supplement markets. Anti-doping bodies added thymosin beta-4 fragments to prohibited lists, and a small number of adverse analytical findings have been reported in competition testing. Published controlled human trials remain scarce. Most mechanistic evidence comes from cell culture and animal models, and those studies examine endpoints such as cell migration, wound closure and inflammation markers. That evidence supports research interest but does not establish clinical benefit, and broad regenerative claims should be read as unverified.
TB-500 is a short synthetic peptide sold under a trade name rather than a systematic chemical name. Suppliers usually describe it as a fragment of thymosin beta-4 and ship it as a lyophilised powder intended for laboratory use. Because the label is commercial, the exact sequence attributed to it is not fully consistent across catalogues, and some listings present a seven-residue peptide while others describe related fragments of similar length. It is not an approved medicine in any major jurisdiction, and it is handled as a research chemical.
Several names appear in scientific and commercial contexts for this peptide. The label TB-500 is informal and does not follow standard biochemical nomenclature. Research articles more often describe the compound as a thymosin beta-4 fragment, Tβ4 fragment, or by its sequence Ac-LKKTETQ. Confusing TB-500 with full-length thymosin beta-4 can lead to incorrect assumptions about activity because the fragment lacks the remaining residues of the parent protein. The relationship between fragment and parent protein remains an active area of study.
Regulatory status differs by country, but TB-500 is not an approved pharmaceutical in major jurisdictions. It is commonly sold as a research chemical for laboratory use, which places responsibility for identity and purity on the supplier and the laboratory. Published human data are limited, and most reports involve preclinical models or cell culture. Questions about whether the fragment mimics all actions of thymosin beta-4, and under which conditions, remain open. Independent verification of any material is therefore a practical requirement in research settings.
Published work involving this sequence spans actin-binding assays, cell-migration studies, wound-healing models, and cardiovascular or musculoskeletal experiments. Much of the biological rationale derives from in vitro systems and animal models, and the number of controlled human studies is small. Reported outcomes vary across preparations, doses, and routes, which complicates comparison between studies. Reviews generally describe the evidence base as preliminary rather than settled. Mechanistic explanations are often proposed by analogy to the parent protein rather than demonstrated directly.
TB-500 is a synthetic seven-amino-acid peptide with the sequence LKKTETQ, corresponding to residues 17 through 23 of the protein thymosin beta-4. The N-terminus is typically acetylated in the described form, giving a monoisotopic mass near 888.5 Da and an average mass of about 889 Da. The designation TB-500 is a catalogue label rather than a formal chemical name, and the same sequence appears in the literature under several alternative abbreviations. It is handled as a research reagent rather than a pharmaceutical product.
On 14 September 2026, a federal judge blocked the administration from imposing fixed time limits on the length of stay for foreign students and journalists without an application for extension. In a separate case, a broad coalition of states filed suit to stop a federal regulation that would permit immigration authorities to deny green cards to immigrants who lawfully use public benefits. These rulings came shortly before the Department of Homeland Security (DHS) regulation was set to take effect on 15 September. Under the proposed limitation, F visas for international students and J visas for cultural exchange programmes in the United States would have been capped at four years. I visas for journalists, which had previously remained valid for years, would have been limited to 240 days.
This transformation of obsidian is accelerated by the presence of water. Although newly formed obsidian has a low water content, typically less than 1% water by weight, it becomes progressively hydrated when exposed to groundwater, forming perlite.
== Functions == ATP is derived from ribose; it contains one ribose, three phosphate groups, and an adenine base. ATP is created during cellular respiration from adenosine diphosphate (ATP with one less phosphate group).
=== Medication === Infective endocarditis: An infection of the endocardium caused by enterococcus; used when the organism is not sensitive to gentamicin Tuberculosis: Used in combination with other antibiotics. For active tuberculosis it is often given together with isoniazid, rifampicin, and pyrazinamide. It is not the first-line treatment, except in medically under-served populations where the cost of more expensive treatments is prohibitive. It may be useful in cases where resistance to other drugs is identified. Plague (Yersinia pestis): Has historically been used as the first-line treatment. However streptomycin is approved for this purpose only by the US Food and Drug Administration. In veterinary medicine, streptomycin is the first-line antibiotic for use against gram negative bacteria in large animals (horses, cattle, sheep, etc.). It is commonly combined with procaine penicillin for intramuscular injection. Tularemia infections have been treated mostly with streptomycin. Streptomycin is traditionally given intramuscularly, and in many nations is only licensed to be administered intramuscularly, though in some regions the drug may also be administered intravenously.
The most efficient jet-propelled organisms are the salps, which use an order of magnitude less energy (per kilogram per metre) than squid. The free-swimming sea slug Phylliroe is notable for being a pelagic hunter that resembles a fish in body plan and locomotion, with functional convergences.
Sources: en.wikipedia.org
Cochran (born 1929), American chemist, known for pioneering studies on the nature of free radicals Ernst Cohen (1869–1944 Auschwitz), Dutch chemist known for work on the allotropy of metals) Mildred Cohn (1913–2009), American chemist, a pioneer in the applying nuclear magnetic resonance to enzyme reactions, particularly reactions of adenosine triphosphate David Collison (PhD 1980), British chemist known for development of electron paramagnetic resonance spectroscopy Vicki Colvin (born 1965), American chemist known for work on the synthesis and characterization of nanomaterials James Bryant Conant (1893–1978), American organic chemist who explored the complex relationship between chemical equilibrium and the reaction rate of chemical processes, Priestley Medal 1944 Elias James Corey (born 1928), American organic chemist, winner of the 1990 Nobel Prize in Chemistry for developing the theory and methodology of organic synthesis, specifically retrosynthetic analysis Robert Corey (1897–1971), American biochemist known for co-discovery of the α-helix and the β-sheet Carl Ferdinand Cori (1896–1984), Czech biochemist, Nobel Prize in physiology or medicine 1947 for discovering how glycogen is broken down and resynthesized Gerty Cori (1896–1957), American biochemist, Nobel Prize in physiology or medicine 1947 for discovering how glycogen is broken down and resynthesized John Cornforth (1917–2013), Australian-British chemist, 1975 Nobel Prize in Chemistry for work on the stereochemistry of enzyme-catalysed reactions Athel Cornish-Bowden (born 1943).
=== Pharmacokinetics === After injection into a vein, 14% of the circulating ioxaglic acid is bound to blood plasma proteins, which is unusually high for a water-soluble iodinated contrast agent. The substance is distributed in the body with a half-life of 12 minutes (range 4 to 17 minutes) and eliminated in unmetabolized (unchanged) form via the kidneys with a half-life of 92 minutes (range 61 to 140 minutes). In people with kidney failure, it is eliminated via the bile duct, saliva or sweat.
== Research and Clinical Frameworks == GCLS faculty and researchers have contributed to publications addressing the development of longevity medicine as a structured field of clinical practice and medical education. A 2025 Biogerontology perspective, authored by Dominik Thor, David Barzilai, Yu-Xuan Lyu and Luiza Spiru, proposed a framework for incorporating longevity-related competencies into continuing medical education and medical curricula. The authors listed GCLS affiliations. Researchers affiliated with GCLS also contributed to the peer-reviewed review article "Toward responsible longevity medicine: Swiss framework for healthy longevity medicine clinics." Published in Longevity, the paper proposed a voluntary framework addressing clinical governance, evidence appraisal, patient safety, data governance and the responsible translation of longevity interventions into clinical practice.
inosine (I, Ino) A naturally occurring, non-canonical nucleoside consisting of a hypoxanthine base with its N9 nitrogen bonded to the C1 carbon of a ribose sugar. Inosine may be incorporated into certain RNA molecules such as the anticodons of some transfer RNAs, and occurs as an intermediate in the breakdown of adenosine to uric acid and in the recycling of adenosine by salvage pathways.
Sources: en.wikipedia.org
==== Saudi Arabia ==== On 15 August 2012 at 11:08 am local time, the Shamoon virus began destroying over 35,000 computer systems, rendering them inoperable. The virus used to target the Saudi government by causing destruction to the state owned national oil company Saudi Aramco. The attackers posted a pastie on PasteBin.com hours prior to the wiper logic bomb occurring, citing oppression and the Al-Saud regime as a reason behind the attack. The attack was well staged according to Chris Kubecka, a former security advisor to Saudi Aramco after the attack and group leader of security for Aramco Overseas. It was an unnamed Saudi Aramco employee on the Information Technology team which opened a malicious phishing email, allowing initial entry into the computer network around mid-2012. Kubecka also detailed in her Black Hat USA talk Saudi Aramco placed the majority of their security budget on the ICS control network, leaving the business network at risk for a major incident. The virus has been noted to have behavior differing from other malware attacks, due to the destructive nature and the cost of the attack and recovery. US Defense Secretary Leon Panetta called the attack a "Cyber Pearl Harbor". Shamoon can spread from an infected machine to other computers on the network. Once a system is infected, the virus continues to compile a list of files from specific locations on the system, upload them to the attacker, and erase them. Finally the virus overwrites the master boot record of the infected computer, making it unusable.
== Protein–DNA interactions == Protein–DNA interactions occur when a protein binds a molecule of DNA, often to regulate the biological function of DNA, usually the expression of a gene. Among the proteins that bind to DNA are transcription factors that activate or repress gene expression by binding to DNA motifs and histones that form part of the structure of DNA and bind to it less specifically. Also proteins that repair DNA such as uracil-DNA glycosylase interact closely with it. In general, proteins bind to DNA in the major groove; however, there are exceptions. Protein–DNA interactions are of mainly two types, either specific interaction, or non-specific interaction. Recent single-molecule experiments showed that DNA binding proteins undergo rapid rebinding in order to bind in correct orientation for recognizing the target site.
===== North America ===== Canada - DMT is classified as a Schedule III drug under the Controlled Drugs and Substances Act, but is legal for religious groups to use. In 2017 the Santo Daime Church Céu do Montréal received religious exemption to use ayahuasca as a sacrament in their rituals. United States - DMT is classified in the United States as a Schedule I drug under the Controlled Substances Act of 1970. In 2019, it was decriminalized, along with other naturally derived psychedelics, in the city of Oakland after a campaign by Decriminalize Nature.
== State and local government == Several states have proposed and passed laws that regulate AI models and AI-generated content, including impersonations, chatbot disclosures, and synthetic political content.
Though clinical scientists have existed in the UK National Health Service for ≈60 years, the introduction of formally-trained and accredited consultant-level clinical scientists is relatively new, and was introduced as part of the new Modernizing Scientific Careers framework developed in 2008. Consultant clinical scientists are expected to provide expert scientific and clinical leadership alongside and, at the same level as, medical consultant colleagues. While specialists in healthcare science will follow protocols, procedures and clinical guidelines, consultant clinical scientists will help shape future guidelines and the implementation of new and emerging technologies to help advance patient care. In the United Kingdom, healthcare scientists including clinical scientists may intervene throughout entire care pathways from diagnostic tests to therapeutic treatments and rehabilitation. Although this workforce comprises approximately 5% of the healthcare workforce in the UK, their work underpins 80% of all diagnoses and clinical decisions.
Sources: en.wikipedia.org
Divide it into single-use aliquots and hold them frozen at -20 °C or below, protected from light. Repeated thawing of one container is the main avoidable source of variability.
Mass spectrometry confirms identity, because the measured mass is compared with the value expected from the sequence. Chromatography mainly reports how much of the material elutes as the target peak.
It usually describes the share of the chromatographic peak area recorded at a set wavelength. Salts, residual water, and solvent are excluded from that number, so it is not the same as mass fraction.
Not necessarily. TB-500 is a commercial label that suppliers apply to synthetic peptides described as thymosin beta-4 or a fragment of it. Published research most often studies the full-length protein, so statements about one do not automatically transfer to the other.